Monitor prescription trends and physician adoption in the first two quarters post-approval. Watch for label expansions in EU, Japan, and China which could further boost revenue. Competitors may respond with pricing or new product announcements.
Price Chart
Executive Summary
AstraZeneca announced FDA approval of Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) for maintenance treatment of asthma in patients aged 12 and older, expanding its indication beyond COPD. The approval is based on positive Phase III KALOS and LOGOS trials showing superior lung function improvement versus dual therapy. This opens a large U.S. asthma market of ~27 million patients, with Breztri already prescribed to 6.8 million patients globally for COPD in 2025.
Key Facts
- Breztri approved in the US for asthma as first and only triple therapy for ages 12+
- Approval based on KALOS and LOGOS Phase III trials demonstrating statistically significant lung function improvement vs dual ICS/LABA therapy
- Breztri was previously approved for COPD in the US in 2020 and prescribed to >6.8 million patients globally in 2025
- Asthma affects 27 million people in the US; ~half are uncontrolled on dual therapy
- Regulatory filings for Breztri in asthma are under review in EU, Japan, and China
Financial Impact
No revenue or financial guidance provided; expands addressable market for Breztri to asthma indication in US, potentially adding significant sales upside beyond COPD franchise
Risk Factors
- Pricing and reimbursement pressures could limit rapid uptake
- Competition from other triple therapies (e.g., GSK's Trelegy) and dual therapies
- Safety or tolerability issues in broader real-world use
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-003979 |
| Document: 0001654954-26-003979-index-headers.html | 0001654954-26-003979 |
| Document: 0001654954-26-003979-index.html | 0001654954-26-003979 |
| Document: 0001654954-26-003979.txt | 0001654954-26-003979 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 6-K | $161.85 $168.37 | ▲ +4.03% | ▲ +1.90% | $156.93 (−3.04%) |
Sep 14, 2026 18d ago | 6-K | $163.78 $168.10 | ▼ −2.64% | ▼ −2.53% | $156.93 (+4.18%) |
Sep 8, 2026 24d ago | 6-K | $160.04 $161.85 | ▲ +1.13% | ▲ +2.25% | $156.93 (−1.94%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $156.93 (−3.26%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $156.93 (−3.26%) |
Sep 1, 2026 4w ago | 6-K | $162.47 $156.94 | ▼ −3.40% | ▼ −3.49% | $156.93 (−3.41%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $156.93 (−3.26%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $156.93 (−3.26%) |
Sep 1, 2026 4w ago | 6-K | $162.47 $156.94 | ▼ −3.40% | ▼ −3.49% | $156.93 (−3.41%) |
Aug 31, 2026 4w ago | Court Ruling | $162.13 $159.95 | ▲ +1.34% | ▲ +1.20% | $156.93 (+3.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access